表在性膀胱腫瘍に対する切除術直後の制癌剤膀注療法

INTRAVESICAL CHEMOTHERAPY IMMEDIATELY AFTER TRANSURETHRAL RESECTION (TUR) FOR THE PROPHYLAXIS OF SUPERFICIAL BLADDER TUMOR

　52例の初発の表在性膀胱腫瘍患者に施行したTUR術後制癌剤膀注（adriamycin：ADM, mytomycin C：MMC, thiotepa）の再発予防効果を検討した．術直後膀注群（35例）と術後1〜2週後膀注群（17例）の比較において，1,3,5年の再発率は，前者の2.9％，16.5％，20.6％に比して，後者では5.9％，24％，39.2％であり，前者が低率であったが，有意差はなかった．膀注前後の血液検査から，重大な副作用は認められず，MMC,ADMによる術直後膀注療法は，従来の膀注療法と同様，有用かつ安全であることが示唆された．

A retrospective study of 52 patients with primary superficial transitional cell carcinoma of the bladder treated by intravesical chemotherapy as prophylaxis after TUR was performed. The group treated immedi-ately after TUR (35 cases) was compared with the group treated 1-2 weeks after TUR (17 cases) in preventing implantation of tumor cells following local resection. The recurrence rate in 1. 3, and 5 postoper-ative years were 2.9 % , 16.5 %, and 20.6 % respectively in the former group, whereas 5.9 %, 24 %, and 39.2 % respectively in the latter. The former was better but not significantly.